Immunodominant B cell epitope in a hotspot mutation site and mechanism of immune escape for SARS-CoV-2
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Recent SARS-CoV-2 variants pose important concerns due to their higher transmissibility ( 1 ) and escape ( 2 ) from previous infections or vaccine-induced neutralizing antibodies (nAb). The receptor binding domain (RBD) of the Spike protein is a major nAb target ( 3 ), but data on its B cell epitopes are still lacking. Using a peptide microarray, we identified an immunodominant epitope (S 415-429 ) recognized by 68% of sera from 71 convalescent Brazilians infected with the ancestral variant. In contrast with previous studies, we have identified a linear IgG and IgA antibody binding epitope within the RBD. IgG and IgA antibody levels for this epitope positively correlated with nAb titers, suggesting a potential target of antibody neutralizing activity. Interestingly, this immunodominant RBD region harbors the mutation hotspot site K417 present in P.1 (K417T) and B.1.351 (K417N) variants. In silico simulation analyses indicate impaired RBD binding to nAb in both variants and that a glycosylation in the B.1.351 417N could further hinder antibody binding as compared to the K417T mutation in P.1. This is in line with published data showing that nAb from either convalescents or anti-CoV-2 vaccinees are less effective towards B.1.351 than for P.1. Our data support the occurrence of immune pressure and selection involving this immunodominant epitope that may have critically contributed to the recent COVID-19 marked rise in Brazil and South Africa, and pinpoint a potential additional immune escape mechanism for SARS-CoV-2.
Article activity feed
-
SciScore for 10.1101/2021.03.11.21253399: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis The statistical power (1-β) of 50 versus 21 individuals for P44 was calculated. Sex as a biological variable Study population: Seventy-one COVID-19 convalescent individuals (52% Female, 48% Male, median age 42 years old) with RT-PCR diagnostic confirmation from March to April 2020 were included in this study. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources To ensure that the secondary antibodies do not interact with the antigen-derived peptides printed on the arrays, one copy of the array was pre-stained with goat anti-human IgG (H+L) DyLight680 … SciScore for 10.1101/2021.03.11.21253399: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis The statistical power (1-β) of 50 versus 21 individuals for P44 was calculated. Sex as a biological variable Study population: Seventy-one COVID-19 convalescent individuals (52% Female, 48% Male, median age 42 years old) with RT-PCR diagnostic confirmation from March to April 2020 were included in this study. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources To ensure that the secondary antibodies do not interact with the antigen-derived peptides printed on the arrays, one copy of the array was pre-stained with goat anti-human IgG (H+L) DyLight680 (Invitrogen, USA) secondary antibody or goat anti-human IgA (chain alpha) DyLight800 (Rockland Immunochemicals Inc., USA) diluted 1:2000 in staining buffer (PBS with 10% blocking buffer) on an orbital shaker at room temperature for 45 min. anti-human IgGsuggested: (Rockland Cat# 609-145-130, RRID:AB_2614820)anti-human IgAsuggested: (Rockland Cat# 609-145-130, RRID:AB_2614820)After three washing steps of 1 min each with 200 µL of the standard buffer, the microarrays were incubated with previously titrated secondary antibodies, anti-IgG and anti-IgA at a dilution of 1:2000, on an orbital shaker at room temperature for 45 minutes. anti-IgGsuggested: Noneanti-IgAsuggested: (LSBio (LifeSpan Cat# LS-C68423-2000, RRID:AB_10634906)Structural analyses: Structural representations of RBD interacting with ACE2 (pdb: 6M0J) and the neutralizing antibody REGN10933 (pdb: 6XDG) were generated using UCSF Chimera (https://www.cgl.ucsf.edu/chimera/). ACE2suggested: NoneExperimental Models: Cell Lines Sentences Resources Therefore, we used 96-well plates containing 5 ×104 cells/mL of Vero cells (ATCC CCL-81). Verosuggested: NoneSoftware and Algorithms Sentences Resources The heatmap was generated using the pheatmap R package (v1.0.12). pheatmapsuggested: (pheatmap, RRID:SCR_016418)The software PyMol (PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC) was used for visualization, mutagenesis and computation of binding regions between molecules. PyMOLsuggested: (PyMOL, RRID:SCR_000305)Statistical analyses: GraphPad Prism 9.0.1 was used for statistical analyses of individual peptide reactivity comparing sera of subjects with high and low neutralization capacity (Mann Whitney) and Spearman for correlation analysis, p values <0.05 were considered statistically significant. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
